{"symbol":"REGN","fiscalQuarter":"Q3-2019","reportDate":"2019-11-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2019","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 6.93%","keyNumbers":[{"metric":"EPS","actual":"$6.67","expected":"N/A","surprise":"+2.63%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["We are pleased with our performance this quarter.","Our pipeline remains strong and we are focused on future growth."],"summary":"Management expressed confidence in the company's performance and highlighted the strength of their product pipeline. They emphasized their commitment to innovation and growth."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong earnings per share beat expectations, which contributed to a 6.93% increase in stock price following the report. The absence of revenue figures leaves some uncertainty, but management's confident tone suggests they are optimistic about future performance. Investors may view this earnings surprise positively as a sign of the company's ongoing strength.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2019 earnings: EPS beat by 2.63%. Stock up 6.93%. Full breakdown."}}